Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin + hengglizin vs metformin in type 2 diabetes with metabolic fatty liver disease
ChiCTR2500108637Phase 4Recruiting
- Sponsor
- Foshan First People's Hospital
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of metformin in type 2 diabetes mellitus (T2DM), Metabolic dysfunction-associated fatty liver disease (MAFLD) and non-alcoholic fatty pancreatic disease (NAFPD) (3 arms), sponsored by Foshan First People's Hospital. Primary endpoints: Liver fat content at 52 weeks, Pancreatic fat content at 52 weeks and 1 more. Started Sep 2025; status: recruiting.
02
Drugs
metformin
03
Conditions
type 2 diabetes mellitus (T2DM)Metabolic dysfunction-associated fatty liver disease (MAFLD)non-alcoholic fatty pancreatic disease (NAFPD)
Beyond the preview
Go deeper on ChiCTR2500108637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108637.